The measure requires Walgreens to prepare a report by June 30 disclosing how the company altered its governance since 2012 to respond to the nationwide crisis. The report must include how the Walgreens board oversees opioid-related programs and whether the executive bonus structure has any opioid-related incentives, such as promoting ethical conduct.
The plan was submitted by the Investors for Opioid Accountability, a group of state treasurers, comptrollers and asset managers. It filed similar measures with drug companies and distributors. The move comes as pharmacies, drugmakers and distributors have increasingly been blamed for helping to fuel the crisis.
Walgreens’ board opposed the plan, arguing that it already discloses how it is handling the risks. However, preliminary results showed shareholders voted in favor of the measure. Final results of the vote will be released in a filing with the U.S. Securities and Exchange Commission, according to the report.
Read the full report here.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.